V.P. and Head of BiometricsEnanta PharmaceuticalsWatertown, Massachusetts, United States
Disclosure information not submitted.
135 - Zelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened Duration of RSV Symptoms in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial in Children 28 Days to 36 Months of Age
Monday, October 20, 202512:35 PM - 12:40 PM US ET
235 - EDP-323, a First-in-Class, Oral, RSV-Specific, Non-Nucleoside L-Protein Inhibitor Antiviral Rapidly Reduces Total RSV Symptoms, Lower Respiratory Tract RSV Symptoms and Viral Load After Human Viral Challenge
Monday, October 20, 20254:15 PM - 4:27 PM US ET
